# Royalty Pharma plc (RPRX) FY2025 Annual P&L / Income Statement

- Company: Royalty Pharma plc (RPRX)
- Period: 2025-01-01 to 2025-12-31
- Filing: FY2025 10-K, filed 2026-02-11, accession number 0001802768-26-000003
- Page: https://plicit.ai/financials/rprx/fy2025-annual-income-statement
- Chart image: https://plicit.ai/charts/rprx-fy2025-annual-income-statement-sankey.png

## Chart details: Revenue by Product and Service

Income statement for 2025-01-01 through 2025-12-31. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total income and other revenues**: 2,378,193,000 US dollars
- **Total operating expense, net**: 818,675,000 US dollars
- **Operating income**: 1,559,518,000 US dollars
- **Total other expense/(income), net**: negative 235,326,000 US dollars
- **Consolidated net income before tax**: 1,324,192,000 US dollars
- **Income tax expense**: 0 US dollars
- **Consolidated net income**: 1,324,192,000 US dollars
- **Income from financial royalty assets**: 2,261,152,000 US dollars
- **Other royalty income and revenues**: 117,041,000 US dollars
- **Provision for changes in expected cash flows from financial royalty assets**: negative 295,838,000 US dollars
- **Provision for credit losses on unfunded commitments**: 89,032,000 US dollars
- **Research and development funding expense**: 452,000,000 US dollars
- **General and administrative expenses (includes $290,890, $3,224, and $3,302 of share-based compensation expense for the years ended December 31, 2025, 2024 and 2023, respectively; see Note 4)**: 573,481,000 US dollars

### Chart connections

- Revenue minus operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to Royalty Pharma plc: $770.95 M; to noncontrolling interests: $553.25 M.